Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 8/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MIF | P14174 | 5/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862149 | 0.86 | S1PR4 (0.44) | S1PR4S1PR1S1PR5S1PR3DGAT1 | |
| SCHEMBL9965883 | 0.84 | KDM4E (0.42) | S1PR4S1PR1S1PR5S1PR3 | |
| SCHEMBL8209905 | 0.84 | KDM4E (0.42) | S1PR4S1PR1S1PR5S1PR3 | |
| SCHEMBL1039190 | 0.84 | KDM4E (0.42) | S1PR4S1PR1S1PR5S1PR3 | |
| SCHEMBL4549611 | 0.83 | NR1H2 (0.35) | S1PR4S1PR1S1PR5S1PR3BRD4 | |
| SCHEMBL13513699 | 0.82 | HTR2C (0.42) | S1PR4S1PR1S1PR5S1PR3 | |
| SCHEMBL13604396 | 0.76 | GUSB (0.43) | — | |
| SCHEMBL3635469 | 0.73 | KDM5A (0.32) | DGAT1BRD4 | |
| SCHEMBL3496533 | 0.72 | KDM1A (0.38) | S1PR4S1PR1S1PR5S1PR3 | |
| SCHEMBL3495575 | 0.72 | KDM1A (0.38) | S1PR4S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | S1PR4 1660/4885S1PR1 943/4885S1PR5 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.